Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.53 (sialidase)
 2,694 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Human anti-S and anti-s eluates bound to glycophorin B on immunoblots from membranes of S+ and s+ red cells, respectively. Eluates of human anti-S were more efficiently prepared from sensitized trypsin-treated cells than from sensitized untreated cells. The results of immunoblotting membranes from enzyme-treated cells confirmed the serological findings: S and s antigens were not affected by treatment with trypsin or sialidase but were destroyed or much depressed by treatment with papain, pronase or alpha-chymotrypsin. Immunoblotting with anti-S or anti-s of membranes from cells with unusual MNS phenotypes confirms the involvement of glycophorin B in hybrid glycophorins; the existence of such hybrid glycophorins was deduced previously from serological work or immunoblotting with monoclonal antibodies. The presence of s-active glycophorin B in glycophorin (B-A)Dantu, in glycophorin BMiIII and in glycophorin (A-B)MiV was confirmed. The bands observed when Mit+ membranes were immunoblotted with anti-S supports the suggestion from serological work that the Mit antigen is associated with an altered S antigen.
 ...
PMID:Immunoblotting of human red cell membranes: detection of glycophorin B with anti-S and anti-s antibodies. 239 72

Polyclonal anti-S react with Met29 of red blood cell (RBC)-bound glycophorin B (GPB) but may also require adjacent amino acids. Treatment of RBCs with certain enzymes and sodium hypochlorite-based bleach (NaClO) affect the interaction of GPB with anti-S. Some, but not all, anti-S react with hybrid glycophorin molecules associated with the TSEN antigen. The purpose of this study was to characterize monoclonal anti-S and to compare their reactivity to polyclonal anti-S in order to determine their potential as blood group reagents and research tools. Furthermore, through inhibition experiments, we attempted to define the epitope recognized by the antibodies. Three monoclonal (MS-93; MS-94; MS-95) and two polyclonal (A1958; X1960) anti-S and a monoclonal anti-GPB (Mab 148) were tested by standard hemagglutination with RBCs of known common and rare phenotype, with S+ RBCs treated with enzymes, with different concentrations of NaClO, and after incubation with synthetic peptides. The anti-S gave different patterns of reactivity. Reactivity with sialidase-treated RBCs showed that MS-93, MS-95, Mab 148, and X1960 recognize sialic acid independent epitopes, whereas MS-94 and A1958 require sialic acid for optimal reactivity. MS-95 and X1960 were strongly reactive with TSEN+ RBCs and only Mab 148 agglutinated S- Dantu+ and S- St(a+) RBCs. MS-94 and Mab-148 agglutinated S+ RBCs treated with NaClO. MS-93 was inhibited only by the 14-mer S-specific synthetic peptide whereas MS-95 was inhibited by all three synthetic peptides containing S-relevant residues. This study clearly demonstrates that different anti-S have different characteristics that should be analyzed before selecting monoclonal antibodies for the basis of reagents for use in the clinical laboratory. These anti-S, because of their varied characteristics, will be useful research tools.
 ...
PMID:Evaluation and comparison of three human monoclonal anti-S, two human polyclonal anti-S, and one murine anti-GPB. 1537 38